Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: Results from exploratory phase i cohorts of CheckMate 143

Neuro-Oncology

Volumn 20, Issue 5, 2018, Pages 674-686

  Omuro, Antonio ^a   Vlahovic, Gordana ^b   Lim, Michael ^c   Sahebjam, Solmaz ^d   Baehring, Joachim ^e   Cloughesy, Timothy ^f   Voloschin, Alfredo ^g   Ramkissoon, Shakti H ^h   Ligon, Keith L ^h   Latek, Robert ^i,j   Zwirtes, Ricardo ⁱ   Strauss, Lewis ⁱ   Paliwal, Prashni ⁱ   Harbison, Christopher T ⁱ   Reardon, David A ^h   Sampson, John H ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h DANA FARBER CANCER INSTITUTE   (United States)

ⁱ BRISTOL MYERS SQUIBB   (United States)

^j KYOWA HAKKO KOGYO CO LTD   (Japan)

more..

Author keywords

CheckMate 143; ipilimumab; nivolumab; PD L1; recurrent glioblastoma

Indexed keywords

IPILIMUMAB; NIVOLUMAB; ANTINEOPLASTIC AGENT;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANEMIA; APPLICATION SITE REACTION; ARTICLE; ASTHENIA; AUTOIMMUNE THYROIDITIS; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CHOLECYSTITIS; CLINICAL ARTICLE; COHORT ANALYSIS; COLITIS; CONFUSION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DERMATITIS; DIABETIC KETOACIDOSIS; DIARRHEA; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; ENDOCRINE DISEASE; EYE DISEASE; FATIGUE; FEMALE; FEVER; GAIT DISORDER; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; HEADACHE; HEPATOBILIARY DISEASE; HUMAN; HYPERGLYCEMIA; HYPERTHYROIDISM; HYPOGLYCEMIA; HYPOMAGNESEMIA; HYPOTHYROIDISM; INFECTION; INFESTATION; KIDNEY DISEASE; LYMPHATIC SYSTEM DISEASE; MACULOPAPULAR RASH; MALE; MEDIASTINUM DISEASE; MENTAL DISEASE; METABOLIC DISORDER; MONOTHERAPY; NAUSEA; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; OPTIC NERVE DISEASE; PANCREATITIS; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRURITUS; RASH; RESPIRATORY TRACT DISEASE; SEPSIS; SKIN DISEASE; THORAX DISEASE; THORAX PAIN; TUMOR RECURRENCE; URINARY TRACT DISEASE; VOMITING; BRAIN TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; FOLLOW UP; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; IPILIMUMAB; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NIVOLUMAB; PROGNOSIS;

EID: 85045155021     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nox208     Document Type: Article

References (44)

1. Ostrom Q T, Gittleman H, Fulop J, et al. CBTRUS statistical report: pri-mary brain and other central nervous system tumors diagnosed in the United States in 2009-2013. Neuro Oncol. 2016;18(suppl 4):iv1-iv75.
2. Preusser M, Lim M, Hafer DA, Reardon DA, Sampson JH. Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat Rev Neurol. 2015;11(9):504-514.
3. Stupp R, Hegi ME, Mason W P, et al; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459-466.
4. National Comprehensive Cancer Network. 2017. NCCN Clinical Practice Guidelines in Oncology. Central Nervous System Cancers. Version I. 2017. Available at https://www.nccn.org/professionals/physician-gls/pdf/cns.pdf. Accessed September 15, 2017.
5. Campos B, Olsen LR, Urup T, Poulsen HS. A comprehensive profle of recurrent glioblastoma. Oncogene. 2016;35(45):5819-5825.
6. Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012;48(14):2192-2202.
7. Brada M, Hoang-Xuan K, Rampling R, et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at frst relapse. Ann Oncol. 2001;12(2):259-266.
8. Reardon DA, Nabors LB, Mason W P, et al; BI 1200 36 Trial Group and the Canadian Brain Tumour Consortium. Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. Neuro Oncol. 2015;17(3):430-439.
9. Raizer JJ, Grimm S, Chamberlain MC, et al. A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer. 2010;116(22):5297-5305.
10. Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the effcacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glio-blastoma. J Clin Oncol. 2013;31(26):3212-3218.
11. Yervoy (ipilimumab) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2017.
12. Opdivo (nivolumab) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2017.
13. Opdivo (nivolumab) [summary of product characteristics]. Anagni, Italy; Bristol-Myers Squibb S.r.l.; Uxbridge, UK: Bristol-Myers Squibb Pharma EEIG; 2017.
14. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372(4):311-319.
15. Motzer RJ, Escudier B, McDermott DF, et al; CheckMate 025 Investigators. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803-1813.
16. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320-330.
17. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123-135.
18. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627-1639.
19. Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recur-rent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856-1867.
20. Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-defcient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182-1191.
21. Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in meta-static urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18(3): 312-322.
22. Weber JS, D'Angelo S P, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375-384.
23. Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17(9):1283-1294.
24. Reardon DA, Freeman G, Wu C, et al. Immunotherapy advances for glio-blastoma. Neuro Oncol. 2014;16(11):1441-1458.
25. Berghoff AS, Kiesel B, Widhalm G, et al. Programmed death ligand 1 expression and tumor-infltrating lymphocytes in glioblastoma. Neuro Oncol. 2015;17(8):1064-1075.
26. Nduom EK, Wei J, Yaghi NK, et al. PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol. 2016;18(2):195-205.
27. Reardon DA, Gokhale PC, Klein SR, et al. Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompe-tent model. Cancer Immunol Res. 2016;4(2):124-135.
28. Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012;13(5):459-465.
29. Queirolo P, Spagnolo F, Ascierto PA, et al. Effcacy and safety of ipili-mumab in patients with advanced melanoma and brain metastases. J Neurooncol. 2014;118(1):109-116.
30. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classifca-tion of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97-109.
31. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assess-ment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology Working Group. J Clin Oncol. 2010;28(11):1963-1972.
32. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122-133.
33. US Department of Health and Human Services. National Cancer Institute. (2009) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Available at https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-5x7.pdf. Accessed July 1, 2017.
34. Sahebjam S, Ramkissoon S, Baehring J, et al. Histopathologic review of suspected disease progression in patients with recurrent glioblastoma (GBM) receiving nivolumab ± ipilimumab: CheckMate 143 [abstract]. J Clin Oncol. 2017;35:2001.
35. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23-34.
36. Han S, Zhang C, Li Q, et al. Tumour-infltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical outcome in glioma. Br J Cancer. 2014;110(10):2560-2568.
37. Antonios J P, Soto H, Everson RG, et al. Immunosuppressive tumor-infl-trating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma. Neuro Oncol. 2017;19(6):796-807.
38. Fecci PE, Mitchell DA, Whitesides J F, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 2006;66(6):3294-3302.
39. Nagane M, Nishikawa R, Narita Y, et al. Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma. Jpn J Clin Oncol. 2012;42(10):887-895.
40. Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozo-lomide for recurrent glioblastoma. Cancer. 2012;118(5):1302-1312.
41. Sepúlveda JM, Belda-Iniesta C, Gil-Gil M, et al. A phase II study of feasibility and toxicity of bevacizumab in combination with temo-zolomide in patients with recurrent glioblastoma. Clin Transl Oncol. 2015;17(9):743-750.
42. Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzas-taurin compared with lomustine in the treatment of recurrent intracra-nial glioblastoma. J Clin Oncol. 2010;28(7):1168-1174.
43. Reardon D, Omuro A, Brandes A, et al. Randomized phase 3 study evaluating the effcacy and safety of nivolumab vs bevacizumab in patients with recurrent glioblastoma: CheckMate 143. Neuro Oncol. 2017;19(suppl 3):iii21.
44. Blumenthal DT, Yalon M, Vainer GW, et al. Pembrolizumab: frst experience with recurrent primary central nervous system (CNS) tumors. J Neurooncol. 2016;129(3):453-460.